Literature DB >> 23751048

Immunization in end-stage renal disease: opportunity to improve outcomes.

Ritu Soni1, Bruce Horowitz, Mark Unruh.   

Abstract

Infection is the second most common cause of death in patients with end-stage renal disease (ESRD), following cardiovascular causes. Immunization is a fairly simple, but underutilized, strategy for prevention of infectious morbidity and mortality in patients with kidney failure. It is imperative for nephrologists and primary care providers to have an understanding of immunization as an essential component of preventive healthcare measures in this high-risk population. Patients with ESRD represent a unique population due to their immunosuppressed state, dialysis-related exposures and suboptimal response to routine vaccines. While the Advisory Committee on Immunization Practices (ACIP) provides guidelines for vaccination of patients with renal disease against Hepatitis B, influenza and pneumococcal disease, the data on immunization against other commonly preventable infectious diseases are lacking. This article reviews the recent evidence on immunization in the ESRD population and synthesizes the related implications for maximizing prevention of infectious diseases in this high-risk population.
© 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23751048     DOI: 10.1111/sdi.12101

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  16 in total

Review 1.  Management of patients with hepatitis B in special populations.

Authors:  Evangelos Cholongitas; Konstantinos Tziomalos; Chrysoula Pipili
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

Review 2.  Influenza and the patient with end-stage renal disease.

Authors:  Brendan T Bowman; Mitchell H Rosner
Journal:  J Nephrol       Date:  2017-05-20       Impact factor: 3.902

3.  Immune Responses of HLA Highly Sensitized and Nonsensitized Patients to Genetically Engineered Pig Cells.

Authors:  Zhongqiang Zhang; Hidetaka Hara; Cassandra Long; Hayato Iwase; Haizhi Qi; Camila Macedo; Massimo Mangiola; Adriana Zeevi; Mohamed Ezzelarab; David Ayares; David K C Cooper; Martin Wijkstrom
Journal:  Transplantation       Date:  2018-05       Impact factor: 4.939

4.  Prolonged SARS-CoV-2 Viral RNA Shedding and IgG Antibody Response to SARS-CoV-2 in Patients on Hemodialysis.

Authors:  Aisha Shaikh; Etti Zeldis; Kirk N Campbell; Lili Chan
Journal:  Clin J Am Soc Nephrol       Date:  2020-10-14       Impact factor: 8.237

5.  Preventive care for patients with end-stage kidney disease: crossroads between nephrology and primary care.

Authors:  Samuel S Phen; Amir Kazory; Shahab Bozorgmehri; Tezcan Ozrazgat-Baslanti; Maryam Sattari
Journal:  Semin Dial       Date:  2020-06-24       Impact factor: 2.886

6.  Clinical analysis of pulmonary infection in hemodialysis patients.

Authors:  Wei Ren; Huixuan Pan; Peng Wang; Lei Lan; Wei Chen; Yan Wang; Lijun Ni; Li Peng
Journal:  Exp Ther Med       Date:  2014-03-28       Impact factor: 2.447

7.  Reducing the risk of infection in end-stage kidney failure patients treated by dialysis.

Authors:  Sophie Collier; Andrew Davenport
Journal:  Nephrol Dial Transplant       Date:  2014-10-08       Impact factor: 5.992

8.  Varicella encephalitis and pneumonia in a patient with end stage renal failure.

Authors:  Lian Leng Low; Farhad Fakhrudin Vasanwala; Sufi Muhammad Suhail
Journal:  Asia Pac Fam Med       Date:  2014-02-21

9.  Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study.

Authors:  Eric Descombes; Filipe Martins; Ould Maouloud Hemett; Veronique Erard; Christian Chuard
Journal:  BMC Pharmacol Toxicol       Date:  2016-02-04       Impact factor: 2.483

10.  ESRD-associated immune phenotype depends on dialysis modality and iron status: clinical implications.

Authors:  Didier Ducloux; Mathieu Legendre; Jamal Bamoulid; Jean-Michel Rebibou; Philippe Saas; Cécile Courivaud; Thomas Crepin
Journal:  Immun Ageing       Date:  2018-07-17       Impact factor: 6.400

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.